

Notice of Allowability	Application No.	Applicant(s)	
	10/541,364	TISI ET AL.	
	Examiner Molly E. Baughman	Art Unit 1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to communication filed 8/20/07 and 12/8/2007.
 2. The allowed claim(s) is/are 1-15, 17-33 and 38.
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- * Certified copies not received: _____.
- Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date 8/20/2007
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date 20071210.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Gary Tanigawa on 12/10/07.

The application has been amended as follows:

CLAIM 33:

a. Please insert --is-- between "acid" and "linked," so that the phrase reads, "the template nucleic acid is linked to an antibody."

2. The following is an examiner's statement of reasons for allowance: No prior art has been found teaching an amplification reaction involving more than one cycle of amplification wherein all the reaction components necessary for both an amplification reaction and a bioluminescence assay are present in the beginning of the reaction (including a polymerase, substrates for the polymerase, at least two primers, luciferin and a thermostable luciferase). The closest prior art teaches all of these components (a polymerase, substrates for the polymerase, at least two primers, luceferin and a thermostable luciferase) present in one reaction mixture, however, the reaction is a primer extension reaction, which does not involve more than one cycle of amplification

(see Nygren et al., "Quantification of HIV-1 Using Multiple Quantitative Polymerase Chain Reaction Standards and Bioluminometric Detection," *Analytical Biochemistry*, 2001, Vo1.288, pp.28-38; Murray et al., US 2004/0185457 A1; and Nyren et al., "Detection of Single-Base Changes Using a Bioluminometric Primer Extension Assay," *Analytical Biochemistry*, 1997, Vol. 244, No.2, pp.367-373). Other methods teach performing the amplification first, and then adding the bioluminescence reaction components to the reaction mixture after the amplification and maintaining the reaction at room temperature or 37°C, where this does not involve the bioluminescence reaction components present during the more than one amplification cycle and at higher temperatures (see). A highly thermostable luciferase is required for such a reaction to occur, which the present invention requires.

Information Disclosure Statement

3. The information disclosure statement (IDS) submitted on 8/20/2007 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. However, some citations have been either modified, or lined through for the following reasons:

b. The references cited in the Search Reports PCT/GB2004/00127 (07/2004 and 07/2005) have been considered, but will not be listed on any patent resulting from this application because they were not provided on a separate list in compliance with 37 CFR 1.98(a)(1). In order to have the references printed on

such resulting patent, a separate listing, preferably on a PTO/SB/08A and 08B form, must be filed within the set period for reply to this Office action.

4. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Molly E. Baughman whose telephone number is 571-272-4434. The examiner can normally be reached on Monday-Friday 8-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Molly E Baughman
Examiner
Art Unit 1637

12/10/07
MEB

KENNETH R. HORLICK, PH.D
PRIMARY EXAMINER

12/10/07